Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601587 | 0.82 | SYK (0.47) | KDRSYKCDK2ABCG2EGFR | |
| SCHEMBL4601257 | 0.81 | KDR (0.53) | KDRCDK2LMNAKDM4ERAB9A | |
| SCHEMBL4601162 | 0.78 | KDR (0.50) | KDRKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL4613372 | 0.78 | KDR (0.50) | KDRSYKVCPCDK2LMNA | |
| SCHEMBL4600388 | 0.78 | KDR (0.50) | KDRVCPCDK2LMNATSHR | |
| SCHEMBL14066777 | 0.78 | KDR (0.50) | KDRCCNA2CDK2KDM4ERAB9A | |
| SCHEMBL4600989 | 0.78 | SMN1; SMN2 (0.58) | KDRLMNATSHRRAB9ASMN1; SMN2 | |
| SCHEMBL4601915 | 0.78 | KDR (0.50) | KDRRAB9ASMN1; SMN2 | |
| SCHEMBL4601132 | 0.78 | KDR (0.62) | KDRCDK2EGFRKDM4ERAB9A | |
| SCHEMBL4601048 | 0.76 | KDR (0.57) | KDRCDK2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101273023-A | 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-24 | — | — | CN | claimed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | claimed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | claimed |
| CN-101273023-A | 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-24 | — | — | CN | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | BMX, CDK1, CKS1B | KDR 1104/4885SYK 301/4885VCP 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.